For Contemporary Pediatrics, Dr Bobby Lazzara discusses a controversial UK-based study published in JAMA Pediatrics that examined how well pharmacologic interventions for attention-deficit/hyperactivity disorder (ADHD) help education and health outcomes for impacted kids.
For Contemporary Pediatrics, Dr Bobby Lazzara discusses a controversial UK-based study published in JAMA Pediatrics that examined how well pharmacologic interventions for attention-deficit/hyperactivity disorder (ADHD) help education and health outcomes for impacted kids.
Dupilumab safe, effective for up to 1 year for atopic dermatitis in infants, preschool children
May 3rd 2024According to new study data presented at the 2024 Pediatric Academic Societies Meeting, dupilumab (dupixent; Sanofi and Regeneron) demonstrated positive safety and efficacy results for up to 1 year in infants and preschool-age children with atopic dermatitis.